Laboratory testing plays an essential role in the diagnosis and management of patients with multiple myeloma. A variety of chemistry and molecular assays are routinely used to monitor patient progress, response to treatment and relapse. Here, we have reviewed current literature and core guidelines on...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Multiple myeloma is cancer of the bone marrow caused by the uncontrolled growth of plasma cells. These cells are one type of white blood cells. Normally, they make antibodies called immunoglobulins to fight infections. In multiple myeloma, cancerous plasma cells multiply rapidly in the bone marrow...
In many cases, myeloma is discovered when blood tests, done as part of a routine physical examination or for some other reason, reveal anemia or a high calcium level, or a high level of protein (or, less commonly, a low level of protein). A urine test may show protein in the urine....
Multiple myeloma (MM) is a malignant plasma cell disease in which tumor cells originate from plasma cells in the bone marrow, and plasma cells are cells that develop to the final stage of function of B lymphocytes. Therefore, multiple myeloma can be classified as B lymphocyte lymphoma. The WH...
The following laboratory tests and complementary examinations were performed:–Blood analysis: see (Table 1).–Bone marrow aspiration (BMA): infiltration by 10% of plasma cells with pathologic features and a myeloma plasma cell immunophenotype.–Skeletal roentgenograms: compression fracture of L2 with...
Multiple Myeloma (Symptomatic), Additional Treatment, Refractory disease and lack of treatment options, modiied: Continue palliative care; consider re-evaluation of goals of care and hospice initiation • Footnote cc added: Folllow up with the tests listed on MYEL-4 under follow-up/surveillance...
Multiple myeloma is a genetically complex, invariably fatal, neoplasm of plasma cells. Cytogenetic and other laboratory tests identify markers to classify newly diagnosed multiple myeloma patients into high, intermediate and standard clinical risk categories. The level of risk reflects the aggressiveness ...
"We developed a drug that could block this signalling mechanism in cancers, but not in normal cells," said Professor Franzoso. "The study showed it worked as effectively as other drugs commonly used to treat patients, killing myeloma cells in laboratory tests and in mice; but unlike existing ...
increasingly recognized that the classical definition of smoldering myeloma using Some studies have shown that patients with certain characteristics, including certain tests such as plain x-rays is outdated. Efforts to modify these criteria IgG levels of >3 g/dL, IgA of >2 g/dL, or urinary ...